PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
7.41%
Growth of 7.41% versus flat Medical - Pharmaceuticals revenue. Walter Schloss would verify growth quality.
6.95%
Cost growth of 6.95% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify cost control.
9.37%
Growth of 9.37% versus flat Medical - Pharmaceuticals gross profit. Walter Schloss would verify quality.
1.83%
Margin change of 1.83% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.74%
Other expenses change of 8.74% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
6.11%
Operating expenses growth near Medical - Pharmaceuticals median of 6.11%. Charlie Munger would verify industry norms.
6.82%
Total costs growth 1.1-1.25x Medical - Pharmaceuticals median of 5.61%. John Neff would investigate control.
-3.70%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
8.37%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 2.05%. Jim Chanos would check for overinvestment.
12.58%
EBITDA growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
4.81%
Margin change of 4.81% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
22.36%
Operating income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
13.92%
Margin change of 13.92% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-108.93%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
0.80%
Pre-tax income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
-6.15%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-6.26%
Tax expense reduction while Medical - Pharmaceuticals median is -3.96%. Seth Klarman would investigate advantages.
5.48%
Net income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
-1.80%
Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
5.48%
EPS growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
5.48%
Diluted EPS growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.